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Abstract: Parkinson’s disease (PD) is a common age-related neurodegenerative disease. Gait impairment
is frequent in the later stages of PD contributing to reduced mobility and quality of life. Digital biomarkers
such as gait velocity and step length are predictors of motor and cognitive decline in PD. Additional gait
parameters may describe different aspects of gait and motor control in PD. Sample entropy (SampEnt),
a measure of signal predictability, is a nonlinear approach that quantifies regularity of a signal. This study
investigated SampEnt as a potential biomarker for PD and disease duration. Real-world gait data over
a seven-day period were collected using an accelerometer (Axivity AX3, York, UK) placed on the low
back and gait metrics extracted. SampEnt was determined for the stride time, with vector length and
threshold parameters optimized. People with PD had higher stride time SampEnt compared to older
adults, indicating reduced gait regularity. The range of SampEnt increased over 36 months for the PD
group, although the mean value did not change. SampEnt was associated with dopaminergic medication
dose but not with clinical motor scores. In conclusion, this pilot study indicates that SampEnt from
real-world data may be a useful parameter reflecting clinical status although further research is needed
involving larger populations.
Keywords: wearable technology; gait; Parkinson’s disease; sample entropy; variability; real-world
1. Introduction
Advances in medicine and public health preventive strategies contribute to the increased life
expectancy of an expanding world population. However, a consequence of greater longevity is increased
morbidity, resulting in the loss of independent living, frailty, and mortality [1]. There are substantial
health and social costs linked to the loss of independence as well as the impact on quality of life of
the individual and careers. A common age-related neurodegenerative disease is Parkinson’s disease
(PD), with a UK incidence of 84 per 100,000 in adults over 50 years [2]. In PD, deep brain structures
controlling movement degenerate and there is progressive loss of motor function. Symptoms of
PD include gait impairment, associated with an increased risk of falling, which is a major health
concern and economic burden [3]. The quantitative analysis of gait may provide biomarkers of disease
progression and offer insight into motor control strategies. Wearable technology, such as accelerometers,
allow for monitoring of ambulatory activity in both controlled and real-world environments [4].
Therefore, data can be collected over an extended period of time when the participant is walking in
familiar surroundings, which provides a more accurate representation of gait compared to walking
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in a gait laboratory [5]. Additionally, analyzing gait through accelerometers offers an inexpensive
and portable solution compared to costly clinical laboratory based measurements [6]. Real-world
gait recordings, however, present several challenges. Firstly, the environment is unconstrained,
unlike a clinical gait laboratory. The terrain will vary, unanticipated obstacles may appear such
as vehicles when crossing the road and frequently the person will perform additional tasks, all of
which will modify gait patterns. However, if the purpose of real-world gait analysis is to capture
the individuals’ gait patterns, this cannot be adequately assessed within the context of an artificial
framework but must incorporate the richness of the environment with which the individual engages.
An essential element when processing large data sets is selecting appropriate features that
encapsulate gait information over extended time-periods. A real-world recording from the triaxial
AX3 accelerometer (Axivity, York, UK) set at 10 bits resolution, sampling at 100 Hz, generates up to
250 MB of raw binary data over seven days. Digital outcomes from real-world recordings include
macro gait measures of walking activity or micro gait measures of specific gait parameters such as
gait velocity, stride time, or step length [7]. Stride time is a measure of rhythmicity and by inference
automaticity of movement [8], which has been extensively examined in people with PD. Rhythmicity
or regularity of stride time can be quantified by linear measures of variability such as the coefficient
of variation (CV). Studies have reported that stride time CV is greater for people with PD compared
to healthy older adults [9], and for freezers compared to nonfreezers [10]. Stride time CV decreases
following dopaminergic medication and is lower in nonfallers compared to fallers [11]. Stride time CV
in healthy adults has also been correlated with cortical activity (supplementary motor area, precentral
gyrus) [12]. Therefore, the variability of stride time would appear as a good indicator of PD and
a risk factor for falls. However, CV and other linear measures of variability are limited as processing
involves averaging values over the recording duration, which does not reflect the natural fluctuations
in metrics over time. This intrinsic signal variability may relate to underlying motor regulation systems.
Nonlinear methods such as entropy, maximum Lyapunov exponent, autocorrelation or recurrence
fluctuation analysis provide a measure of temporal variability and may indicate the integrity of the
underlying motor control system. Two studies on nonlinear variability of stride time, using detrended
fluctuation analysis and long range autocorrelation (LRA), reported more random variability for stride
time in people with PD compared to healthy controls [13,14]. By contrast, Kamath (2015) reported that
the regularity of stride time, assessed with sample entropy (SampEnt), was greater in people with PD
compared to older adults (HOA) [15]. Warlop et al. (2016) reported that a lower Hurst exponent and
α-exponent derived from LRA, indicating more random gait, was associated with a greater disease
level of PD [16].
The application of entropy algorithms to biomedical signals and gait is a common method of
nonlinear analysis [17–21]. Entropy measures the probability that a similar pattern in a signal is repeated
and will be followed by additional similar patterns thus, indicating regularity of the time series [22].
A low value of entropy is indicative of greater regularity whereas a high value suggests a time series
that is to an extent random. Approximate entropy [23] and SampEnt [24] are two types of entropy
measurements. However, approximate entropy has greater bias towards regularity, more sensitivity
to parameter choices, and less relative consistency compared to SampEnt. SampEnt is a robust to
low-level noise, and finite for both stochastic and deterministic processes [22]. Therefore, SampEnt
of gait may be a potential biomarker of PD in addition to indicating disease progression of a disease.
The aims of this pilot study were to: (i) Evaluate the feasibility of evaluating SampEnt on real-world
accelerometry data; (ii) compare real-world SampEnt in PD with respect to HOA; and (iii) investigate
longitudinal changes of SampEnt over 36 months. The hypotheses were that regularity would be lower
(greater SampEnt) in people with PD compared to HOA and that it would decrease over three years
with increasing neurodegeneration.
Sensors 2020, 20, 2631 3 of 14
2. Materials and Methods
2.1. Participants
A subset of participants from the Incidence of Cognitive Impairment in Cohorts with Longitudinal
Evaluation-Gait (ICICLE-GAIT) study [25], which commenced in June 2009, was identified. Ten participants
were selected: Five with PD and five HOAs. Participants were excluded if they had any neurological
(other than PD), orthopedic, or cardiothoracic conditions that may affect their walking or safety during
the testing. Participants with PD were diagnosed with an idiopathic PD according to the UK Parkinson’s
Disease Brain Bank criteria [26].
2.2. Ethics and Consent
The study was approved by the Newcastle and North Tyneside research ethics committee
(ICICLE-GAIT 09/H0906/82) and conducted according to the declaration of Helsinki. All participants
signed an informed consent form prior to testing.
2.3. Demographic and Clinical Measures
At each assessment time-point, participants attended the Clinical Ageing Research Unit,
Newcastle University where demographic information was collected, and clinical testing was performed.
Demographic measures included height, weight, gender, and age of the participant. A trained clinical
examiner rated the severity of PD on the Motor Section (III) of the Movement Disorders Society-Unified
Parkinson’s Disease Rating Scale (MDS-UPDRS-III), approximately 1 h after dopaminergic medication
intake, when the medication generally has its peak clinical effect. The levodopa equivalent daily dose
(LEDD) was also recorded [27], which is a measure of the most commonly prescribed medication
for PD.
2.4. Real-World Data: Equipment and Procedure
Real-world gait data were collected using a single tri-axial accelerometer-based body worn monitor
(BWM) (Axivity AX3, York, UK; dimensions: 23.0 mm × 32.5 mm × 7.6 mm; weight: 11 g; accuracy:
20 parts per million) (Figure 1). This device has previously been validated for recording a high
resolution human movement [28]. The BWM was positioned on the skin overlying the fifth lumbar
vertebra with a hydrogel adhesive and covered with a Hypafix (BSN Medical Limited, Hull, UK)
(Figure 1). The sampling frequency was 100 Hz and the range ± 8 g. The BWM recorded ambulatory
activity continuously for seven days. Seven-day accelerometry data were collected at three time-points
18 months apart (time-points TP1, TP2 = TP1 + 18 months, TP3 = TP2 + 18 months). TP1 was
approximately 36 months after initial diagnosis of PD for the PD group. Participants were asked to
carry out their daily activities as usual and not to alter any routines. On completion of the seven days,
participants returned the device by post to the researchers [7].
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Figure 1. (a) Experimental setup: The site of attachment and orientation of the tri-axial accelerometer 
device on the lower back (L5). In dark grey x (vertical) axis, in black y (mediolateral) axis, and in light 
grey z (anteroposterior) axis. (b) Flowchart of analysis to determine gait events using MATLAB 
functions cumtrapz, cwt, and findpeaks. IC: Initial contact; FC: Final contact. (c) Vertical component of 
accelerometer signal with gait events and stride cycles indicated. 
2.5. Data Processing and Analysis 
The data from the BWM were downloaded and analyzed with a custom-written MATLAB 
program, which has previously been validated [4,29]. The data contained all activity recorded during 
the seven days including sitting, climbing stairs, gardening, and walking. In brief, data were 
segmented by calendar day and axes transformed to orthogonal gravitational vertical, antero-
posterior, and medio lateral axes [30]. Individual ambulatory bouts were identified [31–36] and 
further processed. This method has been validated by comparing gait parameters derived from 
accelerometry data with parameters calculated from a pressure sensitive mat and wearable body-
mounted camera [4,29,32]. Figure 2 shows a segment of BWM output from a real-world data 
recording. 
Figure 1. (a) Experimental setup: The site of attachment and orientation of the tri-axial accelerometer
device on the lower back (L5). In dark grey x (vertical) axis, in black y (mediolateral) axis, and in
light grey z (anteroposterior) axis. (b) Flowchart of analysis to determine gait events using MATLAB
functions cumtrapz, cwt, and findpeaks. IC: Initial contact; FC: Final contact. (c) Vertical component of
accelerometer signal with gait events and stride cycles indicated.
2.5. Data Processing and Analysis
The data from the BWM were downloaded and analyzed with a custom-written MATLAB
program, which has previously been validated [4,29]. The data contained all activity recorded
during the seven days including sitting, climbing stairs, gardening, and walking. In brief, data were
segmented by calendar day and axes transformed to orthogonal gravitational vertical, antero-posterior,
and medio lateral axes [30]. Individual ambulatory bouts were identified [31–36] and further processed.
This method has been validated by comparing gait parameters derived from accelerometry data with
parameters calculated from a pressure sensitive mat and wearable body-mounted camera [4,29,32].
Figure 2 shows a segment of BWM output from a real-world data recording.
Thresholds for activity bout length and stride time were applied to all participants‘ data-sets.
Shorter activity bouts have a greater stride time variability than longer bouts, although their respective
means are similar, centered at approximately 1.2 s (Figure 3). Only bouts of activity between 30 and
60 s were included in the analysis. An inclusion range of 0.5–2.5 s (walking bouts of 12–120 strides)
was applied to the parameter stride time [37] as strides outside these times are atypical.
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2.6. Calculation of Sample Entropy 
Given a time series of N points, SampEnt is defined as the negative natural logarithm of the 
conditional probability that vectors of length m and m + 1 are repeated, with tolerance, r, and no self-
matches [11]. The distance between these repeated vectors, denoted as d[ym(j), ym(k)], is the maximum 
of the absolute distance between corresponding scalar components [38]. Let B be the number of vector 
pairs that satisfy: 
Figure 2. Output data of a body worn monitor for one participant showing vertical, mediolateral,
and anteroposterior acceleration. A longer walking bout 1 and shorter walking bout 2 are indicated.
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Figure 3. Mean stride time for walking bouts of length 1–1000 for a Parkinson’s disease participant,
indicating dependence of stride time on the duration of walking bout. Shaded area indicates
included bouts.
2.6. Calculation of Sample Entropy
Given a time series of N points, SampEnt is defined as the negative natural logarithm of the
conditional probability that vectors of length m and m + 1 are repeated, with tolerance, r, and no
self-matches [11]. The distance between these repeated vectors, denoted as d[ym(j), ym(k)], is the
aximum of the absolute distance between corresponding scalar components [38]. Let B be the nu ber
of vector pairs that satisfy:
d[ym( j), ym(k)] ≤ r (1)
where 1 ≤ j ≤ N − m and 0 ≤ k ≤ m − 1. The number of vectors, Bm, which are significantly different are
calculated and normalized as:
Bm =
B
N −m− 1 (2)
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Repeating the process for vectors of length m + 1, denoting the corresponding value as Bm+1,
SampEnt is then calculated by:
SampEnt(m, r, N) = −ln
⌈
Bm+1
Bm
⌉
(3)
The size of the time series, N, will affect the value of SampEnt with interactions between tolerance
r and vector length m reported [39]. Yentes et al. (2013) observed that a minimum of 200 step parameter
data points are needed for SampEnt to stabilize [40]. However, too large values of N may affect the
calculation of entropy by increasing drift or nonstationarities in the data [41].
SampEnt is dependent on values m and r (Figure 4), therefore, optimal selection is essential.
Values of SampEnt, based on our experimental data, decreases with increasing r, in agreement with
previous studies [40]. In theory, the accuracy of the entropy estimate relies upon the confidence of the
conditional probability and thus, by definition improves with an increased number of matches [41].
Although a short template, m, and wide tolerance r would optimize the number of matches, the entropy
estimate is defined in the limit as m tends to infinity and r tends to zero [42], therefore, a suitable
compromise must be made. A short template length of, for example m = 1, results in a loss of
information as patterns involving longer lengths may not be detected. As the tolerance r increases,
there are increased matches and sample entropy tends to zero, however, features may be missed.
One method of determining m is to fit an autoregressive (AR) model to the data, whereby the optimal
order of the model provides a lower bound for m. If the data came from an autoregressive model
of order p, AR(p), then m ≥ p [42]. The tolerance, r, is here defined as the multiple of the standard
deviation of the data [38]. One method for identifying considers the length of the confidence interval of
the conditional probability estimate. The conditional probability, CP, is an estimate of the probability
of a match of length m + 1 given there is a match of length m, i.e., Bm+1/Bm. If the matches Bm were
independent and fixed, the random variable Bm+1 could be modeled by a binomial distribution and
the variance of the conditional probability, CP(1-CP)/Bm. Lake et al. (2002) [42] has shown that the
estimate of the variance is:
σ2CP =
CP(1−CP)
Bm
+
KBm+1 −KBm(CP)2
B2m
(4)
where KBm is the number of pairs of matching templates of length m that overlap and KBm+1 with
vectors of length m + 1, respectively [38]. The standard error for sample entropy can then be estimated
by σCP /CP, equivalent to the relative error of the conditional probability [38]. For large m and small
r, the sample entropy estimate is assumed to be normally distributed and thus, the 95% confidence
intervals are defined as:
− log(CP) ± 1.96σCP
CP
(5)
The optimal value for r is identified by minimizing the quantity:
max
{
σCP
CP
,
σCP
− log(CP)CP
}
(6)
which is the maximum of the relative error of sample entropy and conditional probability (CP)
estimate, respectively [42].
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Table 1. Participant characteristics and clinical motor scores for a group with Parkinson’s disease. 
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 (yrs) (m) (kg) (kg/m2) TP1 TP2 TP3 TP1 TP2 TP3 
PD1 57.6 1.78 81.8 25.8 25 19 30 580 865 1081 
PD2 61.3 1.73 72.8 24.3 37 43 32 220 300 600 
PD3 65.2 1.76 112.4 36.3 33 34 26 730 483 2031 
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Figure 4. Sample entropy of stride time as a function of tolerance r for averaged m = 1,2,3,4 for
a participant with Parkinson’s disease (PD1) (solid line) and a healthy older adult (HOA1) (dashed line).
2.7. Determining Nonlinearity
Establishi g the pres nce of nonlinearity a priori is essential for the application of nonlinear
tools. The surrogate method offers a statistical approach for identifying nonlinearity with the null
hypothesis testing tha the origi al time series is a linear Gaussian tochastic process [43]. The surr gate
data was generated using the iterated ampli ude-adjusted Fourier trans orm (IAAFT) algorithm [44],
which preserves the amplitude distribution and power spectrum of the original time seri . To test
at the 1% significance level, 99 surrogates wer gener ted, and the Mann–Wh tney rank sum test
was applied.
2.8. Statistical Analysis
Nonparametric statistical tests were applied, given the small number of participants in each group
(n = 5). Mann–Whitney rank sum tests were used to assess the nonlinearity of data. The difference
between sample entropy of the HOA and PD group was tested with the Wilcoxon signed rank test.
The Kendall rank correlation was used to examine associations between SampEnt and clinical features.
The statistical significance was set at p < 0.05.
3. Results
3.1. Demographics
All ten participants were male, aged 67.8 ± 9.8 and 73.4 ± 8.1 years, for the PD and HOA
participants, respectively (Table 1). The UPDRS-III, a measure of motor function, ranged from 19 to 41
(Table 1) indicating mild to moderate motor dysfunction [45]. Table 2 lists the number of strides and
the mean stride times for the thre time-points.
Table 1. Participant characteristics and clinical motor scores for a group with Parkinson’s disease.
ID Age Height Mass BMI MDS-UPDRS-III LEDD
(yrs) (m) (kg) (kg/m2) TP1 TP2 TP3 TP1 TP2 TP3
PD1 57.6 1.78 81.8 25.8 25 19 30 580 865 1081
PD2 61.3 1.73 72.8 24.3 37 43 32 220 300 600
PD3 65.2 1.76 112.4 36.3 33 34 26 730 483 2031
PD4 80.1 1.72 68.6 23.2 36 39 37 475 575 575
PD5 76.5 1.74 89.8 29.7 28 41 41 300 400 500
Mean (SD) 68.1 (9.7) 1.74 (0.02) 85.1 (17.3) 27.9 (5.3) 32(5) 35 (10) 33 (6) 461 (207) 525 (216) 957.4 (643)
HOA1 77.0 1.75 76.4 24.9 - - - - - -
HOA2 61.6 1.75 83.4 27.2 - - - - - -
HOA3 73.8 1.84 110.6 32.7 - - - - - -
HOA4 69.6 1.76 80.6 27.9 - - - - - -
HOA5 84.0 1.74 82.0 27.1 - - - - - -
Mean (SD) 73.2(8.3) 1.77(0.04) 86.6(13.7) 28.0(2.9) - - - - - -
BMI: Body mass index; MDS-UPDRS-III: Movement Disorders Society-Unified Parkinson’s Disease Rating Scale
Part III; TP1: Time-point 1 = 0 months; TP2: Time-point 2 = 18 months; TP3: Time-point 3 = 18 months; LEDD:
Levodopa equivalent daily dose; PD: People with Parkinson’s disease; HOA: Healthy older adults.
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Table 2. Average number of strides analyzed, average strides per bout, and average stride time at
time-points 0, 18, and 36 months.
Group Time (Months) Total Strides Strides Per Bout Stride Time (S)
PD 0 7244 29.7 ± 7.8 1.31 ± 0.21
PD 18 8502 30.7 ± 6.9 1.27 ± 0.17
PD 36 9473 31.7 ± 7.8 1.26 ± 0.17
HOA 0 7563 23.3 ± 5.2 0.93 ± 0.11
HOA 18 10386 29.9 ± 7.2 1.28 ± 0.16
HOA 36 9379 29.0 ± 7.1 1.31 ± 0.18
PD: People with Parkinson’s disease; HOA: Healthy older adults.
Figure 5 shows a heatmap of the maximum relative error of either SampEnt or the conditional
probability for our data, calculated for a range of values of m and r. The scale represents the efficiency
of the entropy estimate. The maximum value of the efficiency metric is when m ≤ 4. Selecting the
maximum value of m = 4 [42], optimum values for r lie between 0.325 and 0.375. Values m = 4 and
r = 0.35 were chosen with a conditional probability ≤ 0.05.
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3.2. Surrogate Analysis
The surrogate data sets for PD and HOA exhibited significantly higher SampEnt values (p < 0.05)
than the actual data sets (Table 3), indicating nonlinearity of the stance time real-world data for
both groups.
Table 3. Sample entropy of original and surrogate time series for people with Parkinson’s disease and
healthy older adults.
Group Time Series p-Value * Surrogate Time Series p-Value **
PD 0.65 ± 0.09
0.008
1.31 ± 0.06 5.95 × 10−5
HOA 0.55 ± 0.11 1.27 ± 0.09 5.95 × 10−5
PD: Person with Parkinson’s disease; HOA: Healthy older adults; * One-tailed Wilcoxon signed-rank test p-value for
PD and HOA SampEnt; ** Mann–Whitney rank sum test p-value.
3.3. Sample Entropy
The PD participants had significantly higher SampEnt values (p = 0.008) across the three time-points
compared to the HOA group (Table 3). There was no significant change in SampEnt between time-points
Sensors 2020, 20, 2631 9 of 14
for either the PD or HOA group. There was a greater range in SampEnt for the PD group at TP3 (0.57)
compared to TP1 (0.14) (Figure 6, Table 4).
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Table 4. Sample entropy for five participants with Parkinson’s disease and five older adults at TP1,
TP2, and TP3.
ID
TP1 TP2 TP3
N SampEnt N SampEnt N SampEnt
PD1 5618 0.68 11,647 0.65 10,721 0.97
PD2 6844 0.55 4691 0.61 7878 0.62
PD3 6800 0.65 6860 0.79 6761 1.06
PD4 7988 0.60 9668 0.53 12,999 0.50
PD5 8970 0.60 9646 0.69 9007 0.79
Mean± SD 7244± 1278 0.61± 0.05 8502± 2729 0.65± 0.09 9473.2± 2455 0.79± 0.24
HOA1 7574 0.27 13366 0.36 12094 0.46
HOA2 6545 0.57 8088 0.53 7204 0.45
HOA3 8716 0.59 9527 0.61 10081 0.62
HOA4 8179 0.46 9156 0.58 7208 0.71
HOA5 6805 0.71 11792 0.51 10308 0.51
Mean± SD 7564 ± 911 0.52 ± 0.17 10386± 2144 0.52 ± 0.10 9379 ± 2131 0.55 ± 0.11
PD: People with Parkinson’s disease; HOA: Healthy older adults; TP1: Time-point 1; TP2: Time-point 2 = TP1 + 18
months; TP3: Time-point 3 = TP2 + 18 months. N: Number of stride cycles analyzed.
3.4. Clinical Features and Sample Entropy
People with PD displayed different changes in progression of the clinical measure of PD motor
severity, UPDRS-III, with two people decreasing their score from time-point 1 to time-point 3, one person
displaying little change and two people increasing their scores (Figure 7a). The dopaminergic medication
level, LEDD, increased for all five participants from time-point 1 to time-point 3 (Figure 7b). There was
no significant association between SampEnt and UPDRS-III (Kendall’s τ = −0.221, p = 0.127). However,
a significant correlation was found between SampEnt and LEDD (Kendall’s τ = 0.394, p = 0.021).
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4. Discussion
This is the first application to our knowledge of nonlinear methods to real-world gait data of
people with PD over an extended time period. The purpose of this study was to examine the feasibility
of applying nonlinear analyses to real-world gait data to identify differences between PD and HOA
groups. Additionally, we aimed to investigate if nonlinear gait metrics could detect changes over
a 36-month period. We hypothesized that regularity would be lower in the PD group and would
decrease over 36 months. Supporting our first hypothesis, people with PD had significantly greater
SampEnt, indicating lower regularity than the HOA group (Table 3) although it did not increase over
time, contrary to our second hypothesis. However, we did observe that there was a positive association
between SampEnt and dopaminergic medication levels, which increased over 36 months for all five
people with PD.
The lower gait regularity we observed in the PD group may be explained by the greater number
of adjustments needed to overcome the increasing instability resulting from impaired sensorimotor
integration [46]. Our results are in agreement with two previous studies, which applied recurrence
fluctuation analysis and LRA to determine nonlinear variability [14]. This suggests more random gait
dynamics in people with PD. However, Kamath (2015) reported that SampEnt of stride time was lower
in people with PD (1.27 ± 0.12) compared to healthy adults (1.71 ± 0.13) [15]. This conflicting result may
be explained by their parameter selections (vector length m = 3, threshold r = 0.15, number of strides
N = 400), younger control group (39.5 ± 18.5 years), and different walking paradigm [15]. Additionally,
Kamath reported a shorter stride time and lower standard deviation for the PD group (1.11 ± 0.05 s)
and control group (1.07 ± 0.02 s), reflecting the different types of walking data.
Although SampEnt was greater for the PD group, we did not observe any increase over 36 months,
contrary to our hypothesized decrease in regularity over time there was, however, an increase in
range from TP1 to TP3 in the PD group whereas the range of SampEnt for the HOA group decreased.
The absence of change in SampEnt may be related to the varying stages of motor dysfunction, indicated
by the MDS-UPDRS-III motor score ranging from 19–43 and different patterns of progression of
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movement disorder, with no consistent increase or decrease in the PD cohort. A study investigating
dynamic postural SampEnt similarly observed increased variability in PD compared to HOA but no
change over three years [17]. A further consideration is that the dopaminergic medication will modify
gait parameters. A positive correlation between SampEnt and the dosage of dopaminergic medication,
which increased over thirty-six months, was observed. One interpretation of this association is that
LEDD is an indicator of the severity of the disease, therefore, greater SampEnt is associated with greater
disease severity. A different interpretation is causal and is that the effect of dopaminergic medication
is to increase stride time variability. However, previous studies have reported reduced stride time
variability [47] and greater regularity of ankle joint kinematics [48] when in the ON medication
state. Interpretation of LEDD is difficult as a recent study reported that people who had a greater
motor response to a levodopa challenge test were prescribed higher levels of LEDD and exhibited
reduced deterioration in motor function, quantified by the UPDRS-III score, in the eighteen months
prior to the levodopa challenge test [49]. A final factor, which may affect gait due to dopaminergic
medication is levodopa induced dyskinesia, abnormal movement patterns that develop directly as
a result of dopaminergic medication [50]. However, we thresholded the strides for duration, which is
likely to minimize inclusion of gait associated with dyskinesias. One major issue, when considering
the association between SampEnt and dopaminergic medication is that there was no constraint in
medication levels during recording as gait recordings were collected during the entire day when
participants would have been in both the ON and OFF states.
There are several limitations to this study. As this was a feasibility study, data from only a small
number of PD and HOA were processed, which reduces the statistical power. The number of strides
analyzed, N, differed between participants. Although we did not find a correlation between N and
SampEnt, we did not investigate the interactions between m and r. However, given that the minimum
number of strides examined for each participant was over 4600, SampEnt is expected to have stabilized
and not to change with the increasing N. Future work will include extracting nonlinear parameters
from other gait metrics and domains from a larger number of participants. Additional nonlinear
measures will be determined such as local dynamic stability or the correlation dimension.
5. Conclusions
Analysis of 262,735 strides during real-world walking over a 36-month period indicated
significantly lower regularity of stride time in people with Parkinson’s compared to healthy age-matched
older adults. The novelty of this study is that we analyzed real-world gait, recorded over seven days,
during a 36-month period. The importance of real-world gait data is that not only are changes in internal
gait timing systems monitored but also responses to external perturbations assessed as individuals
undertake complex walking tasks such as crossing roads, turning corners, talking, and adjusting speed.
Additionally, real-world data recorded over several days incorporate circadian variations, different
levels of dopaminergic medication reflecting both the ON and OFF states, day to day fluctuations in
mood, and variations in daily activities, which may modify gait. The lower regularity of stride time in
people with PD may reflect not only deterioration of dopaminergic neurons within the basal ganglia
but also changes in other subcomponents such as the postulated spinal central pattern generator
circuits controlling gait and the response to external environmental perturbations. Although some
variability of gait parameters is desirable, indicating flexibility and ability to adjust to perturbations,
too high a variability implies an unstable control system and instability leading to falls. We did not
observe an increase in sample entropy with disease duration, which may be due to the small sample
size and heterogeneity of the individual participants in addition to the effect of medication. However,
we did observe a positive correlation between SampEnt and LEDD, the dopaminergic medication daily
dose. Further investigation is needed to determine underlying causes for this association. In summary,
applying sample entropy algorithms to real-world data shows potential as a method to differentiate
people with PD from HOA. However, it is essential that appropriate vector lengths and thresholds are
established, and signals are tested for nonlinearity. Further analyses are essential, involving greater
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numbers of participants, applying different methods of nonlinear analysis, investigating different gait
parameters, and relating the nonlinear measures to functional measures.
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Abbreviations
The following abbreviations are used in this manuscript:
BWM Body worn monitor
CV Coefficient of variation
HOA Healthy older adults
LRA Long range autocorrelation
MDS-UPDRS Movement Disorder Society-Unified Parkinson’s Disease Rating Scale
PD Parkinson’s disease
SampEnt Sample entropy
TP1 Time-point 1 (36 months after initial diagnosis for people with Parkinson’s)
TP2 Time-point 2 = TP1 + 18 months
TP3 Time-point 2 = TP2 + 18 months
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